Nant Capital, LLC
SEC CIK 1675758 · EDGAR
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| IBRX | ImmunityBio, Inc. | 10% | 129.23M | — | — | 1 | 2023-09-11 | 2023-09-11 |
Most active insiders at IBRX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Simon Barry J. | Dir | — | $4.14M |
| 2 | Selecky Christobel | Dir | — | $3.00M |
| 3 | Cohen Cheryl | Dir | — | $1.25M |
| 4 | Sachs David C. | CFO | — | — |
| 5 | Adcock Richard | CEO, Pres, Dir | — | — |
| 6 | CALIFORNIA CAPITAL EQUITY, LLC | 10% | — | — |
| 7 | LAUER REGAN J | CAO | — | — |
| 8 | SOON-SHIONG PATRICK | See remarks, Dir, 10% | — | — |
Nant Capital, LLC made no open-market trades at IBRX in the last 12 months.
Transactions 1
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DMI | 2023-09-13 | 2023-09-11 | IBRX | ImmunityBio, Inc. | Nant Capital, LLC | 10% | J - Other | $1.29 | +209.29M | 129.23M | New | +$269.99M |
Purchase Sale Sale after option exercise All abbreviations